Erman Akkus, Medical Oncology Fellow at Ankara University, shared on X/Twitter:

“Adjuvant Aspirin in Breast Cancer

The Alliance A011502 randomized phase 3 trial.

Negative study, lack of benefit for invasive DFS and OS.

3020 participants
high-risk nonmetastatic breast cancer
Aspirin vs placebo
By median follow-up of 33.8 months,
invasive DFS, HR:1.27 (95% CI, 0.99-1.63; P = .06)
OS, HR: 1.19 (95% CI, 0.82-1.72).”

Visit the article website.
Source: Erman Akkus/X